News & Updates

Show Multimedia Only
SMAD7 overexpression boosts EGFR-CAR-T function against NSCLC

SMAD7 overexpression boosts EGFR-CAR-T function against NSCLC

10 Sep 2023

Epidermal growth factor receptor (EGFR)-mothers against decapentaplegic homologue 7 (SMAD7)-Chimeric antigen receptor (CAR) T-cell therapy against nonsmall-cell lung cancer (NSCLC) is on a par with EGFR-dominant‒negative transforming growth factor (TGFbeta) receptor 2 (DNR)-CAR-T in terms of efficacy and resistance to negative TGFβ regulation, a study has shown.

SMAD7 overexpression boosts EGFR-CAR-T function against NSCLC

10 Sep 2023
Better assessment of energy requirements needed in CRC patients

Better assessment of energy requirements needed in CRC patients

07 Sep 2023
Anti-HER-2/neu vaccine may benefit gastric cancer patients

Anti-HER-2/neu vaccine may benefit gastric cancer patients

06 Sep 2023 byAudrey Abella

In patients with HER-2-overexpressing metastatic or advanced gastric/gastroesophageal (G/GEJ) adenocarcinoma, a regimen comprising standard-of-care chemotherapy and a HER2-targeting peptide vaccine induced antibody responses that corresponded with tumour size reduction, according to an analysis of the HERIZON study which looked into the correlation between antibody responses and clinical outcomes.

Anti-HER-2/neu vaccine may benefit gastric cancer patients

06 Sep 2023